<img src="https://ml.globenewswire.com/Resource/Download/33089548-b62b-412d-9343-ae38d8b720c6?size=2" nborder="0" align="left" hspace="5" vspace="5" title="AssemblyBio_logo_RGB.png" alt="Assembly Biosciences, Inc."/>SOUTH SAN FRANCISCO, Calif., May 11, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, chief medical officer, will present during the Bank of America Securities 2026 Global Health Care Conference at 4:35 p.m. Pacific Time on May 13, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: <a href="https://www.globenewswire.com/Tracker?data=qgV7mfWCIitCHwjYdfsZ5-rjC1xpyZ4pXCpLmYMfYDp-FKcuLfcI3BZXsCYs4QD8MM9wrqwIelWISrjcYLIHe0iTACJdTJhTIgnLVc2izsCJ8sKfJQbuPEpKjDshCp8cA1fb7hCn3-nv8O7dgBZzebjleGDmZAM8QiZ9z3gtGK1mNDKmdK_88Do_B7dUQ-EX" rel="nofollow" target="_blank" title="">https://investor.assemblybio.com/events-presentations</a>. About Assembly Biosciences Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data may not differentiate Assembly Bio’s product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources necessary to continue its research activities, clinical studies and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Investors: Patrick Till Meru Advisors (484) 788-8560 <a href="https://www.globenewswire.com/Tracker?data=xkMwX5HNszlgZuzY-dDG_ubkJ7UiKEDe0oSyEbYpV-BIbisxap-oVghhp0wue0cA0WXr9IX9CBQJElISCuxKmU96rbLRozpl9dOkr59nqp9DiAo9yPerQ2_cQx3nIDYTrNyGSOw54tIB8MBoSWqwPA==" rel="nofollow" target="_blank" title="investor_relations@assemblybio.com">investor_relations@assemblybio.com</a> Media: Sam Brown Healthcare Communications Jaime Strachota (703) 819-7647 <a href="https://www.globenewswire.com/Tracker?data=8RiDiGP0J6iOJOprT3-zqCgTC4dSqu2xQ75GsYyYUcxWLWJOBOyfuf8pM_00NdrqHbyrlRlc4i1GlPIif6MNC3y_zFWNqFdo7xGkXPWbQxQ=" rel="nofollow" target="_blank" title="ASMBMedia@sambrown.com">ASMBMedia@sambrown.com</a> <img alt="" src='https://ml.globenewswire.com/media/NjFhOGFjYTYtMWEyMS00MDhiLTllZTItYjIzOTgyZTc3MDVmLTEwMzk3NzAtMjAyNi0wNS0xMS1lbg==/tiny/Assembly-Biosciences-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn